cancer-research-structural-biochemistry-2019-tracks

10 / 17

Page 28
Volume 3
August 5-6, 2019 | Singapore
CANCER RESEARCH AND PHARMACOLOGY
STRUCTURAL BIOCHEMISTRY, STEM CELLS AND MOLECULAR BIOLOGY
24th International Conference on
International Congress on
&
Cancer Research 2019 & Structural Biochemistry 2019
August 5-6, 2019
Journal of Cancer and Metastasis Research
Testing the efficacy of vitamin D3 and metformin to retard the development of
subcutaneous ehrlich ascites carcinomas in-vivo
Prashant kumar M V
JSS Medical College, India
Vitamin D3 and metformin are widely used in
humans for regulating mineral metabolism
and blood glucose levels, respectively. Interestingly
these two agents have also shown to exhibit chemo
preventive effects against various carcinoma cells
in vitro and in vivo. But it is not known, whether
combining these two anti-cancer agents helps in
synergistic tumor growth inhibition. Therefore, in
this study the potency of combining Vitamin-D3
and Metformin was investigated against EAC cells
injected solid tumor model. Experimentally, EAC bearing mice were given Vitamin D3 (125μg/kg and 250μg/kg) and Metformin
(125mg/kg and 250mg/kg) alone or in combination (VD3 125μg/kg + M 125mg/kg) in a simultaneous and sequentially treatment
regimens and tumor weight recorded at the end of the experiment. Analysis of the data showed an about 52% and 59% growth
inhibition with VD3 125μg/kg and 250μg/kg, respectively, whereas the administration of Metformin yielded 57% and 62%
growth inhibition at 125mg/kg and 250mg/kg, respectively. Simultaneous administration of 125μg/kg VD3 and 125mg/kg
Metformin reduced the tumor weight by 63% indicating a marginal increase in the treatment efficacy. However, no such increase
in the efficacy was observed when these two drugs administered sequentially. Mechanistically, VD3 and Metformin inhibited the
development of blood vessels and induced apoptosis in tumors. In conclusion, our data suggest simultaneous administration of
VD3 and Metformin for treating cancers.
Biography
Prashanth kumar M V is an Indian council of medical research (ICMR) Senior Research Fellow at Centre for excellence in Molecular
Biology and Regenerative Medicine (CEMR), Department of Biochemistry, JSS Medical College, JSS Academy of Higher Education
and Research (JSS- AHE&R), Mysuru. His work focuses on developing the combination therapies on anti-cancer agent for treating
breast cancers by repurposing the existing drugs. He has identified Vitamin D3 and Anti-diabetic drug Metformin combination for breast
cancer treatment in vitro and in vivo model. As a Principle Investigator he has received research fund from the home university for his
excellence work on V-D3 and Metformin as anti-cancer agents on Breast cancer cell line. He has published his work in national and
international reputed peer reviewed journals. He has Presented posters, delivered an oral talk as delegate speaker and received best
oral presentation award in national and international conferences.